Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens

被引:97
作者
Berberich, C
Ramírez-Pineda, JR
Hambrecht, C
Alber, G
Skeiky, YAW
Moll, H
机构
[1] Univ Wurzburg, Inst Mol Biol & Infect Dis, D-97070 Wurzburg, Germany
[2] Univ Leipzig, Inst Immunol, Coll Vet Med, Leipzig, Germany
[3] Corixa, Seattle, WA 98104 USA
关键词
D O I
10.4049/jimmunol.170.6.3171
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Upon loading with microbial Ag and adoptive transfer, dendritic cells (DC) are able to induce immunity to infections. This offers encouragement for the development of DC-based vaccination strategies. However, the mechanisms underlying the adjuvant effect of DC are not fully understood, and there is a need to identify Ag with which to arm DC. In the present study, we analyzed the role of DC-derived IL-12 in the induction of resistance to Leishmania major, and we evaluated the protective efficacy of DC loaded with individual Leishmania Ag. Using Ag-pulsed Langerhans cells (LC) from IL-12-deficient or wild-type mice for immunization of susceptible animals, we showed that the inability to release IL-12 completely abrogated the capacity of LC to mediate protection against leishmaniasis. This suggests that the availability of donor LC-derived IL-12 is a requirement for the development of protective immunity. In addition, we tested the protective effect of LC loaded with Leishmania homolog of receptor for activated C kinase, gp63, promastigote surface Ag, kinetoplastid membrane protein-11, or Leishmania homolog of eukaryotic ribosomal elongation and initiation factor 4a. The results show that mice vaccinated with LC that had been pulsed with selected molecularly defined parasite proteins are capable of controlling infection with L major. Moreover, the protective potential of DC pulsed with a given Leishmania Ag correlated with the level of their IL-12 expression. Analysis of the cytokine profile of mice after DC-based vaccination revealed that protection was associated with a shift toward a Th1-type response. Together, these findings emphasize the critical role of IL-12 produced by the sensitizing DC and suggest that the development of a DC-based subunit vaccine is feasible.
引用
收藏
页码:3171 / 3179
页数:9
相关论文
共 62 条
  • [31] STRUCTURALLY DISTINCT GENES FOR THE SURFACE PROTEASE OF LEISHMANIA-MEXICANA ARE DEVELOPMENTALLY REGULATED
    MEDINAACOSTA, E
    KARESS, RE
    RUSSELL, DG
    [J]. MOLECULAR AND BIOCHEMICAL PARASITOLOGY, 1993, 57 (01) : 31 - 46
  • [32] EPIDERMAL LANGERHANS CELLS ARE CRITICAL FOR IMMUNOREGULATION OF CUTANEOUS LEISHMANIASIS
    MOLL, H
    [J]. IMMUNOLOGY TODAY, 1993, 14 (08): : 383 - 387
  • [33] DENDRITIC CELLS IN LEISHMANIA MAJOR-IMMUNE MICE HARBOR PERSISTENT PARASITES AND MEDIATE AN ANTIGEN-SPECIFIC T-CELL IMMUNE-RESPONSE
    MOLL, H
    FLOHE, S
    ROLLINGHOFF, M
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (03) : 693 - 699
  • [34] LANGERHANS CELLS TRANSPORT LEISHMANIA-MAJOR FROM THE INFECTED SKIN TO THE DRAINING LYMPH-NODE FOR PRESENTATION TO ANTIGEN-SPECIFIC T-CELLS
    MOLL, H
    FUCHS, H
    BLANK, C
    ROLLINGHOFF, M
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1993, 23 (07) : 1595 - 1601
  • [35] Dendritic cells as vectors for vaccination against infectious diseases
    Moll, H
    Berberich, C
    [J]. INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY, 2001, 291 (05) : 323 - 329
  • [36] Dendritic cell regulation of TH1-TH2 development
    Moser, M
    Murphy, KM
    [J]. NATURE IMMUNOLOGY, 2000, 1 (03) : 199 - 205
  • [37] EXPRESSION CLONING OF A PROTECTIVE LEISHMANIA ANTIGEN
    MOUGNEAU, E
    ALTARE, F
    WAKIL, AE
    ZHENG, SC
    COPPOLA, T
    WANG, ZE
    WALDMANN, R
    LOCKSLEY, RM
    GLAICHENHAUS, N
    [J]. SCIENCE, 1995, 268 (5210) : 563 - 566
  • [38] Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
    Nestle, FO
    Alijagic, S
    Gilliet, M
    Sun, YS
    Grabbe, S
    Dummer, R
    Burg, G
    Schadendorf, D
    [J]. NATURE MEDICINE, 1998, 4 (03) : 328 - 332
  • [39] Piccotti JR, 1998, J IMMUNOL, V160, P1132
  • [40] Prina E, 1996, J IMMUNOL, V156, P4318